Download GVN Virology Confirmed Faculty Robert C. Gallo Prof. Robert Gallo

GVN Virology
Confirmed Faculty
Robert C. Gallo
Prof. Robert Gallo is Founder and Director of the Institute of Human Virology (IHV) at the University of
Maryland. Prior to this role, he spent 30 years at the National Institutes of Health's National Cancer
Institute, where he was head of its Laboratory of Tumor Cell Biology. Dr. Gallo is renowned for his
research on HIV, most notably his co-discovery in 1984 that HIV is the cause of AIDS. His research
has been instrumental to the development of HIV blood tests and HIV therapies. In 1996, his
discovery that a natural compound known as chemokines can block HIV and halt the progression of
AIDS was hailed by Science magazine as one of that year’s most important scientific breakthroughs.
Dr. Gallo’s current work at the IHV combines the disciplines of research, patient
care, and prevention programs in a concerted effort to speed the pace of medical
breakthroughs. Dr. Gallo has authored more than 1,200 scientific publications, as
well as the book "Virus Hunting: AIDS, Cancer & the Human Retrovirus: A Story of
Scientific Discovery." Dr. Gallo has been awarded 31 honorary doctorates and was
twice a recipient of the Albert Lasker Clinical Medical Research Award (1982 and
1986). He is a member of the National Academy of Sciences and the Institute of
Medicine.
William Blattner
William A. Blattner, MD is Co-Founder and Associate Director of the Institute of Human Virology (IHV)
and Professor of Medicine and Chief, Division of Cancer Epidemiology at University of Maryland,
School of Medicine. He is an internationally recognized authority on HIV/AIDS and has a long track
record of domestic and global health leadership. He co-founded the Institute of Human Virology at
the University of Maryland with Drs. Robert C. Gallo and Robert R. Redfield. He is a pioneer in
research studies of the first human retrovirus, HTLV-1 and the AIDS virus, HIV-1. Blattner not only has
substantial experience of direct relevance to HIV program management, he is also is an internationally
recognized research scientist who has authored or co-authored over 350 peer
reviewed papers, 70 book chapters and made numerous scientific presentations at
national and international meetings. He has served in advisory capacity to NIH, CDC,
US Military and to numerous pharmaceutical and biomedical industry leaders. From
2003 – 2012, he has served as a Mayoral appointee to the Baltimore Commission on
HIV/AIDS and provided strategic guidance to the City and its Health Department on
implementing well- coordinated and evidence-based programs.
C. David Pauza
Dr. Pauza received the PhD in 1981 from the University of California, Berkeley. From 1981-1985, he was
a postdoctoral fellow and staff member of the Laboratory of Molecular Biology at the Medical
Research Council, Cambridge, England. In 1985 Dr. Pauza moved to the Salk Institute for Biological
Studies in La Jolla, California where he started the AIDS Research Program and guided its
development until 1990 when he accepted an appointment at the University of
Wisconsin-Madison. Dr. Pauza created the Immunology and Virology Division at
the Wisconsin National Primate Center and established strong interdisciplinary
programs in AIDS involving basic, clinical, and animal models research. After 10
years at the University of Wisconsin, Dr. Pauza moved to the Institute of Human
Virology as Professor in the Basic Science Division and, since 2004, Assistant
Director. In addition to 25 years in laboratory, animal model and clinical studies on
HIV/AIDS, Dr. Pauza has an active program in tumor immunology with efforts to pioneer new
approaches for clinical management of disease through immunotherapy. Dr. Pauza has authored
over 160 original monographs and is actively funded by the National Institutes of Health, USA and by
the Gates Foundation.
Robert Redfield
Dr. Robert R. Redfield has been actively engaged in clinical research and clinical care of chronic
human viral infections and infectious diseases, especially HIV, for more than 30 years. He served as
the founding director of the Department of Retroviral Research within the Military’s HIV Research
Program and retired after 20 years of service in the US Army Medical Corp when he co-founded the
University of Maryland’s Institute of Human Virology with Dr. William Blattner and Dr. Robert C. Gallo.
He is currently a Professor of Medicine, Professor of Microbiology and Immunology, and serves as the
IHV Associate Director and Director of the Division of Clinical Care and Research.
Dr. Redfield made several important early contributions to our understanding of
HIV, to include the demonstration of the importance of heterosexual transmission
and the development of the Walter Reed staging system for HIV infection.
Presently, Dr. Redfield oversees an extensive clinical program providing HIV care
and treatment to more than 5,000 patients in the Baltimore/Washington DC
community. He also leads extensive USG funded global care and treatment, and
post-graduate medical education programs, which are currently active in 5 African
and 2 Caribbean countries.
Albert Osterhaus
Ab Osterhaus is the Head of the Institute of Virology of the Erasmus Medical Center. He has a broad
experience in leading research projects in the fields of vaccine development and
immunopathogenesis of virus infections of man and animals. He holds many editorial appointments
for scientific journals, is the holder of several patents, and from 1980 onwards has
held over 50 consultantships. Over the last 25 years, Prof. Osterhaus has identified
more than a dozen "new" viral pathogens. He is author of more than 580 peer
reviewed scientific papers. He is also Director of the National Influenza Center (NIC),
Rotterdam, Director WHO Global Reference Laboratory for Measles, Head of WHO
National Reference Laboratory for Measles and Rubella with RIVM Bilthoven, Director
WHO Collaborating Centre for Arboviruses and Haemorrhagic Fever Reference and
Research, and Professor of Wildlife Virology and Virus Discovery, University of
Utrecht.
Yutaka Tagaya
Dr. Tagaya is Head, T-cell Biology Lab, Division of Basic Sciences and Vaccine Research, Institute of
Human Virology, at the University of Maryland School of Medicine. Dr. Tagaya received his M.D. and
Ph.D. degrees from Kyoto University Medical School, and completed postdoctoral studies at the
National Cancer Institute. While at the NCI, Dr. Tagaya made seminal discoveries in the field of
cytokine biology. He has been recognized as one of the international leaders in this field. He has
discovered a unique way IL-15 functions in vivo (trans-presentation paradigm) and generated animal
models to study the biology of cytokines and, through his work, has demonstrated a direct correlation
between cytokines and some illnesses such as leukemia and autoimmune diseases. Currently Dr.
Tagaya's group at the IHV studies the molecular mechanism of CD8 T cell
differentiation in special connection to a transcription factor IRF-8. Dr. Tagaya's
group is also developing novel anti-cytokine drugs that may be used to treat
autoimmune and inflammatory diseases using the animal models his group has
generated in the past. His group also studies the leukemic mechanism associated
with HTLV-1. His bibliography contains more than 60 publications in reputed
journals in the field of cytokine biology, molecular and cellular immunology.
David Thomas
David L. Thomas, M.D., is a world-renowned expert on hepatitis C and has been a faculty member at
The Johns Hopkins University School of Medicine since 1993. He has been Director
of the School’s Division of Infectious Diseases since 2006. Dr. Thomas has focused
most of his research efforts over the past two decades on liver infections, especially
the causes and treatments for hepatitis C, the leading cause of liver disease in the
United States and an infection that kills an estimated 10,000 to 12,000 Americans
each year. He is author of hundreds of articles and many book chapters on various
aspects of hepatitis, and has also investigated how co-infections with hepatic C
viruses and HIV progress in intravenous drug users with weakened immune
systems.
Rohit Talwani
Dr. Talwani is Medical Director of the Hepatitis Clinical Unit at the US Veterans Affairs
Medical Center in Baltimore and an Assistant Professor at the University of Maryland
Medical School. He is an infectious disease specialist, specializing in the treatment of
chronic hepatitis infection. Dr. Talwani received his M.D. from the University of South
Carolina in 1995
Konstantin Chumakov
Dr. Chumakov is the Associate Director for Research, Center for Biologics Evaluation and Research Office of Vaccines Research and Review, U.S. Food & Drug Administration.
He is recognized
worldwide for his knowledge of vaccine development and efficacy, particularly in relation to polio. His
research program is studying certain adverse reactions caused by oral polio vaccine
(OPV) that require treatment. His group’s research program focuses on creating,
validating, and using new biotechnology tools for in-depth studies of the molecular
makeup of vaccines and for studying how people respond to vaccines. They base
their approach to this research on the concept of molecular consistency; that is, on
ensuring that manufacture of vaccines results in products that are uniform in their
molecular makeup. Dr. Chumakov is the author of over 120 scientific articles.
Diane Griffin
Dr. Griffin is the Alfred and Jill Sommer Professor and Chair in Molecular Microbiology and
Immunology at the Bloomberg School of Public Health at Johns Hopkins University. She is
recognized as a world renowned expert in measles. Dr. Griffin has studied the host immune responses
to viral infections since her early days at Johns Hopkins University. Her career has centered on two
primary areas of research including the neurovirulence of Sindbis virus and immunosuppression
induced by human measles virus. This knowledge has been critical to her latest
vaccine efforts using Sindbis virus particles expressing the measles hemagglutinin
protein. Her studies pinpoint the difficulty involved in clearing measles virus from
the human body. Furthermore, her work may lead to a new vaccine that could be
delivered to infants in developing countries where this virus is still a major public
health problem. She is a member of the American Academy of Microbiology, US
National Academy of Sciences, Institute of Medicine, the Maryland Women's Hall of
Fame, and has received the Pioneer Award from the International Society for
Neurovirology.
Peter Palese
Dr. Palese is Professor and Chair of the Department of Microbiology in the Icahn School of Medicine
at Mount Sinai in New York. He is known worldwide for his expertise in the field of RVA viruses to
include influenza, paramyxo and corona (SARS) viruses. His research group is interested in
fundamental questions concerning the genetic make-up and the biology of viruses using molecular
biological techniques to understand how viruses replicate and how they interact with cells to cause
disease in their hosts. Dr. Palese is the author of multiple book chapters and more
than 300 scientific publications. He is on the editorial board for Proceedings of the
National Academy of Sciences and has been awarded multiple patents on viral
vaccines and antivirals. Palese is a member of the US National Academy of Sciences,
the Institute of Medicine, the Austrian Academy of Sciences, and the German
Academy of Sciences Leopoldina. Among his honors are the Robert Koch Prize, the
Charles C. Shepard Science Award, the European Virology Award, and the SanofiInstitut Pasteur Award.
Jose Esparza
Dr. Esparza is an internationally recognized expert on global health, vaccinology and HIV/AIDS. From
2004 to 2014 he was with the Bill & Melinda Gates Foundation in Seattle WA, first as Senior Advisor on
HIV Vaccines and subsequently as Senior Advisor on Global Health (Vaccines.) Now retired from the
Gates Foundation and living in Reston VA, Dr. Esparza provides expert advice to different
organizations. From 1974 to 1986 he worked at the Venezuelan Institute of Scientific Research, one of
the most important research institutions in Latin America, where he became Professor of Virology and
Chair of the Center for Microbiology and Cell Biology. He published seminal work in the field of
rotaviruses, combining basic science with epidemiology and clinical work. From 1986
to 2004 Dr. Esparza worked with the World Health Organization (WHO) and the
Joint United Nations Programme on HIV/AIDS (UNAIDS), in Geneva, Switzerland,
where he became a global leader in the field of HIV vaccines. Dr. Esparza is author
of over 180 publications, and has served in numerous advisory committees all over
the world. He is a member of the Venezuelan Academy of Medicine and of the
Royal Academy of Doctors of Spain.
Barry Beaty
Dr. Beaty is known internationally for his work and leadership in infectious diseases. His major
research efforts have been in the epidemiology and control of vector-borne and rodent-borne
diseases. His work to understand the epidemic and evolutionary potential of diseases, such as
dengue, yellow fever, West Nile fever, LaCrosse encephalitis, and hantavirus pulmonary syndrome,
and to control these dread diseases is and has been funded by the National Institutes of Health, the
Centers for Disease Control, the World Health Organization, the MacArthur Foundation, the Gates
Foundation and other agencies. Beaty is also known internationally for his research in mosquito vector
biology, molecular biology, vector pathogen interactions, and vector control. Dr. Beaty is a Member
of the National Academy of Sciences, a fellow of the American Academy of
Microbiology, and a CSU University Distinguished Professor. At CSU, Dr. Beaty was
the founder and former Director of the Arthropod-borne Infectious Diseases
Laboratory, Director of the Rocky Mountain Regional Center of Excellence for
Biodefense and Emerging Infectious Diseases, and Director of the Infectious Disease
Supercluster and Chief Scientific Officer of MicroRx, the business arm of the ID SC.
Connie Schmaljohn
Dr. Schmaljohn is an internationally recognized expert on hantaviruses and hemorrhagic fever with
renal syndrome. Following postdoctoral research, she joined the Virology Division at USAMRIID in
1983 and served as Chief of the Molecular Virology Branch from 1992-2006. Her current position is as
the Army’s Senior Research Scientist for Medical Defenses Against Infectious Diseases (ST). She is one
of only 42 Army senior professional scientists. Dr. Schmaljohn’s research focuses on
basic molecular virology research and on the design and testing of molecular
vaccines for highly pathogenic viruses. She is the author of more than 120 research
publications, holds numerous patents and serves on several editorial boards. Dr.
Schmaljohn was elected to the American Academy of Microbiology in 2007 and is
currently the Chair of the American Society for Microbiology Biodefense Conference
and the President of the International Society for Hantaviruses. Schmaljohn received a Ph.D. in
Microbiology/Virology from Colorado State University in 1978.
Reed Shabman
Dr. Reed Shabman is an Infectious Disease Investigator at the J. Craig Venter Institute (JCVI). The goal
of Dr. Shabman’s current research is to understand the interplay between zoonotic viruses and their
hosts. Specific areas of interest include defining the host immune response following infection,
identifying unique mechanisms of viral gene expression, and discovering novel viral innate immune
evasion strategies. Knowledge within these areas will aid in the development of
successful vaccines and therapeutics to counteract virus infection. His most recent
work is focused on the highly virulent filoviruses (Ebola and Marburg virus), which
are classified as NIAID Category A Priority Pathogens and CDC Bioterrorism Agents.
To accomplish these research goals, Dr. Shabman is actively integrating next
generation sequencing technologies at JCVI. Dr. Shabman received his Ph.D. in
2008 from the Department of Microbiology and Immunology at the University of
North Carolina at Chapel Hill.